Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chou-Chen Chen

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Anticancer Research|October 26, 2022
The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma SusceptibilityTe-Cheng Yueh, Hao-Yuan Tsao, Wei-Ching Chien, et al.
Anticancer Research|March 6, 2020
Association of <i>Adiponectin</i> Genotypes With Colorectal Cancer Susceptibility in TaiwanYi-Chih Hung, Wen-Shin Chang, An-Kuo Chou, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
Nutrients|July 14, 2023
Efficacy and Safety of a Parenteral Nutrition Program for Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching StudyYu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, et al.
American Journal of Cancer Research|January 8, 2024
Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registryChou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, et al.
American Journal of Cancer Research|January 13, 2025
Outcomes of upfront primary tumor resection in patients with synchronous <i>RAS</i> wild-type metastatic colorectal cancerPo-Jung Chen, Chou-Chen Chen, Shih-Ching Chang, et al.
American Journal of Cancer Research|August 15, 2025
Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with <i>RAS</i> wild-type metastatic colorectal cancer: a nationwide real-world studyChing-Wen Huang, Chou-Chen Chen, Shih-Ching Chang, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Anticancer Research|October 26, 2022
The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma SusceptibilityTe-Cheng Yueh, Hao-Yuan Tsao, Wei-Ching Chien, et al.
Anticancer Research|March 6, 2020
Association of <i>Adiponectin</i> Genotypes With Colorectal Cancer Susceptibility in TaiwanYi-Chih Hung, Wen-Shin Chang, An-Kuo Chou, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
Nutrients|July 14, 2023
Efficacy and Safety of a Parenteral Nutrition Program for Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching StudyYu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, et al.
American Journal of Cancer Research|January 8, 2024
Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registryChou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, et al.
American Journal of Cancer Research|January 13, 2025
Outcomes of upfront primary tumor resection in patients with synchronous <i>RAS</i> wild-type metastatic colorectal cancerPo-Jung Chen, Chou-Chen Chen, Shih-Ching Chang, et al.
American Journal of Cancer Research|August 15, 2025
Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with <i>RAS</i> wild-type metastatic colorectal cancer: a nationwide real-world studyChing-Wen Huang, Chou-Chen Chen, Shih-Ching Chang, et al.
Pageof 2